To manage the complex but mutually beneficial network of politicians and merchants, the city of Venice established and maintained a variety of innovative legal and regulatory structures.
This created reliable and trustworthy places of exchange and effective methods of conflict resolution between the different classes, countries, cultures, religions, and empires.
The area around the Rialto Bridge was Venice's most important market and served as a center for information, banking, and financial services. Today, we would call it a place or platform for collaborative networking.
Finding mutually beneficial compromises between the interests of all parties involved was a challenge in those days and is a challenge now. Overcoming this challenge through professional negotiations is the key to success for all business parties involved.
I am an experienced negotiator with strong marketing background. My main strengths are exploring and understanding the interests and needs of the negotiation partners, finding win-win solutions agreeable to all parties involved, focusing on project specific priorities, structuring complex processes and communicating understandably.
Over 3 decades in the Pharmaceutical industry I gained experience in the fields of Strategic Planning, Sales, Marketing and Business Development & Licensing within Schering and Bayer. As VP Negotiations I was responsible for the negotiation of Term Sheets, Contracts, Contract Amendments and Manufacturing & Supply Agreements.
I have a degree in Economics, worked in the UK (Brighton) and in the US (New York) and live in Germany (Berlin).
Building on my expertise in women’s health I supported the Danish company Cirqle Biomedical in partnering for its OUI project for on-demand, non-hormonal contraception. I supported Cirqle in preparing its corporate presentation, contacted all potential commercial partners in the field, conducted discussions on terms with interested parties, and negotiated the final global research collaboration and license agreement with the US company Organon. The contract was signed in July 2022 and is considered a benchmark deal in the difficult and conservative field of women’s health.
For further details please see the joint press release.